4D Molecular Therapeutics Q2 EPS $(0.77) Up From $(0.87) YoY, Sales $239.00K Up From $162.00K YoY
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics (NASDAQ:FDMT) reported Q2 losses of $(0.77) per share, an 11.49% improvement YoY. The company also reported a 47.53% increase in sales to $239.00K YoY.
August 09, 2023 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
4D Molecular Therapeutics reported improved Q2 earnings with losses narrowing and sales increasing YoY.
4D Molecular Therapeutics reported an improvement in their Q2 earnings with losses narrowing by 11.49% YoY and sales increasing by 47.53% YoY. This indicates a positive financial performance which could potentially lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100